4 completed, 2 unknown. 4 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Not applicable | 1 | Unknown 1 |
| Phase 4 | 1 | Unknown 1 |
Follow long-chain-aldehyde dehydrogenase: new trials by email Literature Review of long-chain-aldehyde dehydrogenase trials Research Report on long-chain-aldehyde dehydrogenase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline - Pain, Healthy Volunteers | Phase 1 | Completed | Bayer | 42 | 2024-07-23 | 2024-09-19 |
| Primary Irritation Patch Test (PIPT) Study Conducted at NovoBliss Research for Shared Panel Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide, Peptide complexed HA Age Defying Gel with Natural Extracts, Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts - Healthy | Not applicable | Unknown | NovoBliss Research Pvt Ltd | 26 | 2022-12-05 | 2022-12-14 |
| A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations Chlorhexidine Gluconate, Hibi Universal Bathing System, 0.1% SLS - Skin Irritancy Potential | Phase 4 | Unknown | Molnlycke Health Care AB | 44 | 2021-06-01 | 2021-06-28 |
| Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design MOB015B, 0.2% SLS, 0.9% Saline - Erythema | Phase 1 | Completed | Moberg Pharma AB | 45 | 2017-10-19 | 2024-04-17 |
| A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C) - Heart Failure, Congestive | Phase 1 | Completed | GlaxoSmithKline | 18 | 2016-10-01 | 2017-01-25 |
| Study to Investigate the Irritation Potential of GSK1940029 Gel 0.3% GSK1940029 gel, 1% GSK1940029 gel, 0.3%/1% vehicle gel only - Acne Vulgaris | Phase 1 | Completed | GlaxoSmithKline | 54 | 2013-10-14 | 2017-05-09 |
Acne Vulgaris (1) · Erythema (1) · Heart Failure (1) · Pain (1)
GlaxoSmithKline (2) · Bayer (1) · Moberg Pharma AB (1) · Molnlycke Health Care AB (1) · NovoBliss Research Pvt Ltd (1)
United States (4) · Australia (1)
Dr Nayan K Patel, MBBS (1) · Jonathan S Dosik, MD (1) · Kendra Drake (1)